Cost-utility analysis of 21-gene assay for node-positive early breast cancer.
Conclusions: Use of the 21-gene rs assay could be a cost-effective strategy for Ontario patients with estrogen receptor-positive, her2-negative early bca and 1-3 positive lns.
PMID: 31708649 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
More News: Breast Cancer | Canada Health | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Genetics | Health Management | HER2 | Hormonal Therapy | Hormones | Study | Women